Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18108949 | 0.92 | HDAC6 (0.41) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16804322 | 0.90 | METAP2 (0.40) | METAP2CHRM4 | |
| SCHEMBL18852703 | 0.88 | HDAC6 (0.43) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16804406 | 0.86 | HDAC6 (0.44) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16804193 | 0.85 | HDAC6 (0.50) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16804179 | 0.84 | HDAC1 (0.47) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16804276 | 0.83 | HDAC6 (0.46) | HDAC6HDAC1HDAC4HDAC8HDAC2 | |
| SCHEMBL16794772 | 0.83 | DGAT1 (0.38) | METAP2CHRM4 | |
| SCHEMBL16804342 | 0.82 | METAP2 (0.39) | METAP2 | |
| SCHEMBL16804178 | 0.82 | HDAC6 (0.51) | HDAC6HDAC1HDAC4HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080125-B1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-10-10 | — | — | EP | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC5, HDAC1, HDAC2 | HDAC6 4/4885HDAC1 2/4885HDAC4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.